FINNENCE ▪ THE WIRE FILE
THE WIRE · № 62472
News■ Unclear/unknown
DryEye Rescue Becomes Exclusive U.S. Distributor of ScoutPro by Bausch + Lomb
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-02 18:47 UTC
LAST UPDATE2026-10-02 18:47 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Private distribution deal for a diagnostic product; no public-company financials disclosed.
Small private distribution news, no ticker impact
CATALYST TO WATCH
Any disclosed sales figures, absent here
MAIN RISK
Assuming Bausch + Lomb earnings effect
FULL DISPATCH
BOCA RATON, Fla., Oct. 2, 2026 /PRNewswire/ -- DryEye Rescue announced that it is now the exclusive distributor of ScoutPro in the United States, with Bausch + Lomb continuing direct sales. ScoutPro, osmolarity test cards, and control solutions are available now through DryEye Rescue and...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
In HelloNation, Education Expert Chelsea Gianni Highlights Healthcare Career Options in Northern West Virginia2026-10-02 18:52 UTC
In HelloNation, Education Expert Chelsea Gianni Highlights Healthcare Career Options in Northern West Virginia2026-10-02 18:52 UTC
→CORRELATIONshares Healthcare
$500K health insurance increase looms for Mount Olive despite smaller rate hike2026-10-02 18:26 UTC
$500K health insurance increase looms for Mount Olive despite smaller rate hike2026-10-02 18:26 UTC
→CORRELATIONshares Healthcare
Angel Aligner ersetzt in Europa die „Torque Ridges" durch „Pressure Points"2026-10-02 18:56 UTC
Angel Aligner ersetzt in Europa die „Torque Ridges" durch „Pressure Points"2026-10-02 18:56 UTC
→CORRELATIONshares Healthcare
Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL2026-10-02 19:05 UTC
Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL2026-10-02 19:05 UTC
→CORRELATIONshares Healthcare
NeuroSense Provides Update on Nasdaq Listing Compliance2026-10-02 20:15 UTC
NeuroSense Provides Update on Nasdaq Listing Compliance2026-10-02 20:15 UTC
←CORRELATIONshares Healthcare
New Phase 3 trial: Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) — Regeneron Pharmaceuticals2026-10-02 12:00 UTC
New Phase 3 trial: Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) — Regeneron Pharmaceuticals2026-10-02 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.